Pierrel Logo

Pierrel

Pharmaceutical firm specializing in dental anesthetics and contract manufacturing.

PRL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005549644
LEI:
8156002BC7CB6E3BD403
Country:
Italy
Address:
STRADA STATALE APPIA 7 BIS, 46/48, 81043 CAPUA

Description

Pierrel is a global pharmaceutical company specializing in oral health. With over 70 years of experience, the company focuses on the development, production, registration, and licensing of dental anesthetics and complementary medical devices. Its core expertise lies in the aseptic manufacturing of injectable drugs. The product portfolio includes a wide range of dental anesthetics marketed under its own brands, such as Orabloc®, Ubisestin™, Xylestesin™, and Mepivastesin™. In addition to its branded products, Pierrel offers medical devices for oral pathology screening, prevention, and regeneration. The company also provides contract manufacturing services to the pharmaceutical and life science industries. Its production facilities are authorized by major global regulatory agencies, including the EMA and FDA, ensuring compliance with high international quality standards.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-24 12:25
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 249.0 KB
2024-01-17 19:37
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 262.6 KB
2023-12-20 20:07
Pierrel S.p.A.: Comunicato ai sensi dell’art. 41, co. 6 RE, emesso da PRL S.p.A…
Italian 261.4 KB
2023-12-15 21:19
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE, emesso da PRL SpA
Italian 230.9 KB
2023-12-14 20:16
Pierrel S.p.A.: Comunicato ai sensi degli artt. 36 e 43 del Regolamento adottat…
Italian 227.0 KB
2023-11-29 11:28
Pierrel S.p.A.: Bilancio d'esercizio al 31.12.2022
Italian 4.9 MB
2023-11-28 21:23
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE - emesso da PRL S.p.A. …
Italian 242.8 KB
2023-11-24 23:43
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 2 RE,emesso da PRL S.p.A.…
Italian 221.8 KB
2023-11-24 19:28
Pierrel S.p.A.: IL CDA DI PIERREL APPROVA IL COMUNICATO DELL’EMITTENTE IN REL. …
Italian 256.7 KB
2023-11-22 22:55
Pierrel S.p.A.: PRL S.p.A. OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA …
Italian 203.6 KB
2023-11-16 15:43
Pierrel S.p.A.: Informazioni essenziali Addendum al patto parasociale – 16 nove…
Italian 310.4 KB
2023-11-16 15:40
Pierrel S.p.A.: Estratto Addendum al patto parasociale – 16 novembre 2023
Italian 1.2 MB
2023-11-15 11:03
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1, del Regolamento - AVVI…
Italian 133.7 KB
2023-10-31 17:18
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1,emesso da PRL S.p.A. e …
Italian 141.2 KB
2023-10-24 11:11
Pierrel S.p.A.: Comunicato ai sensi dell’art. 102, comma 3, del D.Lgs. 24 febbr…
Italian 215.6 KB

Automate Your Workflow. Get a real-time feed of all Pierrel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pierrel

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pierrel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Camp4 Therapeutics Corp Logo
Develops RNA-based therapeutics to amplify protein expression for genetic diseases.
United States of America
CAMP
Camurus Logo
Develops and commercializes long-acting medicines for severe and chronic diseases.
Sweden
CAMX
Candel Therapeutics, Inc. Logo
Develops viral immunotherapies to activate the immune system to fight cancer.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
Israel
CANF
Cannabotech Ltd. Logo
Develops therapies by integrating cannabinoids and medicinal mushroom extracts.
Israel
CNTC
Cannovum Cannabis AG Logo
Licensed importer, wholesaler, and manufacturer of medical cannabis products.
Germany
27N0
Cantargia Logo
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
Sweden
CANTA
Cantourage Group SE Logo
Produces and distributes EU-compliant medical cannabis from international partners.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
A clinical-stage biotech developing cell and exosome-based biologics for serious diseases.
United States of America
CAPR
A clinical-stage biotech developing regenerative medicines for heart failure.
United Kingdom
N/A

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.